Glyx Therapeutics will participate in BioFIT 2025, taking place in Strasbourg on December 2 and 3, 2025. As one of Europe's leading partnering events for early-stage innovation in life sciences, BioFIT offers a direct channel to engage investors, industrial partners, and technology transfer stakeholders as Glyx advances its Seed round and prepares its lead candidate for clinical proof-of-concept.

Glyx Therapeutics will take part in the 6th edition of the Trinational HealthTech Days, organized by Quest For Health, the health incubator of the Grand Est region. The event brings together health innovations, investors, and strategic partners across the tri-national ecosystem, and offers Glyx a direct opportunity to advance new investor relationships as it prepares its Seed round.

Glyx Therapeutics will participate in Deeptech Connect, taking place at Le Centquatre in Paris in November 2025. As a flagship gathering for France's deeptech ecosystem, the event provides a direct channel to engage investors, industrial partners, and technology transfer stakeholders as Glyx advances its Seed round and prepares its lead candidate for clinical proof-of-concept.

On September 4, 2025, the Haute Autorité de Santé (HAS) issued Decision n°2025.0204/DC/SEM, refusing to grant early access (accès précoce) to Lecanemab (Leqembi) in France. The decision applies to the treatment of adult patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease, non-carriers or heterozygous for the ApoE ε4 allele, with confirmed amyloid pathology. At Glyx Therapeutics, we follow this development closely, as it underscores the scientific and